NeuroMetrix, Inc. (Nasdaq: NURO), announced after hours yesterday a one-for-six reverse stock split of its common stock, effective immediately. Shares now trade under the symbol NUROD. This is in line with my article last month predicting a late August or early September reverse split. Expect EPCT to be the next to announce a reverse split, likely within the next two to three weeks.
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) today announced the sale of 6,252,252 shares of common stock to three institutional investors in a registered direct offering at a public offering price of $1.11 per share. The gross proceeds of the offering are expected to be approximately $7 million.
VIVUS, Inc. (NASDAQ: VVUS) announced after hours a PDUFA date of avanafil, for the treatment of erectile dysfunction (ED) of April 29, 2012.
Trius Therapeutics, Inc. (NASDAQ:TSRX) filed a $100m shelf after hours yesterday.
SuperGen, Inc. (NASDAQ: SUPG), announced it anticipates that it will begin operating under the name Astex Pharmaceuticals, Inc. on September 12, 2011. The new name follows the previously announced closing of its acquisition of Astex Therapeutics Limited, a privately held, UK-based biotechnology company developing targeted therapies. Astex Pharmaceuticals, Inc. is expected to begin trading on NASDAQ under the symbol ASTX on September 12, 2011.